Thuja Capital
Professor Daan Crommelin, PhD, is presently vice-chair of the scientific advisory board of the European Innovative Medicines Initiative (IMI). He was also professor at the department of Pharmaceutics at Utrecht University, and adjunct professor at the University of Utah. Daan was Chief Scientific Officer of Octoplus, a company specialized in product formulations and drug delivery systems. He published over 260 articles and book chapters and is on the editorial board of 10 peer reviewed journals. He chaired the board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP), was chair of the organizing committee of the Pharmaceuticals Sciences World Conference 2007 in Amsterdam and was president of the European Federation of Pharmaceutical Sciences (EUFEPS). Professor Crommelin is a scientific advisor to various venture capital firms and pharmaceutical and biotechnology companies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Thuja Capital
Thuja Capital is an early-stage venture capital firm located in Utrecht, The Netherlands. They invest in product-focused companies that aim to have a true impact on patients and doctors alike, as demonstrated in clinical studies to enable a health claim.